Rezolute, Inc. develops therapies for rare and metabolic diseases, with recent company updates centered on hypoglycemia caused by hyperinsulinism. Its principal news themes include ersodetug, the Phase 3 sunRIZE study in congenital hyperinsulinism, the Phase 3 upLIFT study in tumor hyperinsulinism, and clinical evidence from continuous glucose monitoring, biomarker analyses and expanded access experience.
Rezolute news also covers FDA interactions, presentations at pediatric endocrinology and life sciences meetings, quarterly financial results, business updates and investor conference participation. The company’s updates generally connect clinical-program progress with regulatory engagement, cash resources and development priorities for its hyperinsulinism pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
RZ402 is an oral therapy under development by Rezolute aimed at providing a less invasive treatment for Diabetic Macular Edema (DME), an eye condition linked to diabetes. During a recent KOL event, Dr. Robert Bhisitkul highlighted RZ402's potential to change DME treatment by reducing the burdens associated with current intravitreal injections. Rezolute launched a Phase 2 study in December 2022 to assess RZ402’s safety and efficacy, with top-line results expected in Q1 2024. This could address the increasing prevalence of DME, which affects over a million individuals in the U.S.
Rezolute, Inc. (Nasdaq: RZLT) is set to host a virtual conference call on March 22, 2023, at 4:30 p.m. EDT, to discuss its RZ402 Phase 2 clinical program for diabetic macular edema (DME). The event will feature expert insights from Dr. Robert Bhisitkul of UCSF. RZ402, a novel oral plasma kallikrein inhibitor, aims to improve DME treatment, traditionally reliant on invasive anti-VEGF injections. Preclinical results show RZ402 can reduce retinal vascular leakage by up to 90%, and early studies indicate strong bioavailability and safety. The company also plans to highlight its RZ358 program entering Phase 3 later this year.
Rezolute, Inc. (Nasdaq: RZLT) announced its second-quarter financial results for fiscal 2023, highlighting its ongoing clinical advancements. The company initiated a Phase 2 proof-of-concept study for RZ402 aimed at treating diabetic macular edema and is preparing for a global Phase 3 study for RZ358 for congenital hyperinsulinism. As of December 31, 2022, cash and cash equivalents stood at $146.7 million. Research and development expenses increased to $10.9 million from $9.5 million year-over-year, attributed to higher personnel costs. General and administrative expenses also rose to $3.4 million from $2.7 million. The net loss for the quarter was $13.6 million, compared to $12.6 million in the prior year.
Rezolute, Inc. (RZLT) announced the initiation of a Phase 2 proof-of-concept study for RZ402, an oral plasma kallikrein inhibitor aimed at treating Diabetic Macular Edema (DME). This milestone addresses the unmet needs of DME patients, who currently rely on cumbersome anti-VEGF eye injections. The study will evaluate RZ402's safety and efficacy over a 12-week period across approximately 100 participants. RZ402 shows promise based on prior positive Phase 1b trial results and aims to improve treatment compliance and clinical outcomes for DME.
Rezolute, Inc. (RZLT) announced positive results from its clinical programs and a $130 million financing to advance RZ358 and RZ402. The company plans to initiate a Phase 2 proof-of-concept study for RZ402, an oral plasma kallikrein inhibitor for diabetic macular edema, by year-end. RZ358, a treatment for congenital hyperinsulinism, demonstrated significant hypoglycemia event reduction. Financially, cash and cash equivalents stood at $154.3 million, with a net loss of $9.8 million for Q1 fiscal 2023, signaling increased R&D expenses.